Porin involvement in cephalosporin and carbapenem resistance of Burkholderia pseudomallei

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Aunkham, Anuwat ^a   Schulte, Albert ^a   Winterhalter, Mathias ^b   Suginta, Wipa ^a  

^a SURANAREE UNIVERSITY OF TECHNOLOGY   (Thailand)

^b JACOBS UNIVERSITY BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMOXICILLIN; CARBAPENEM; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ENROFLOXACIN; GENTAMICIN; IMIPENEM; KANAMYCIN; MEROPENEM; NORFLOXACIN; PENICILLIN G; PHENYLALANINE; PORIN; TYROSINE; 17927 D; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; RECOMBINANT PROTEIN; THIENAMYCIN DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BURKHOLDERIA INFECTION; BURKHOLDERIA PSEUDOMALLEI; DRUG SENSITIVITY; ESCHERICHIA COLI; GENE MUTATION; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MEMBRANE PERMEABILITY; NONHUMAN; PROTEIN EXPRESSION; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MELIOIDOSIS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MUTATION; PERMEABILITY; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; BETA-LACTAM RESISTANCE; BURKHOLDERIA PSEUDOMALLEI; CEPHALOSPORINS; ESCHERICHIA COLI; HUMANS; MELIOIDOSIS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PERMEABILITY; PORINS; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; THIENAMYCINS;

EID: 84900426506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095918     Document Type: Article

References (42)

1. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ (2006) Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nature Rev Microbiol 4: 272-282.
2. Peacock SJ (2006) Melioidosis. Curr Opin Infect Dis 19: 421-428.
3. Aldhous P (2005) Melioidosis? Never heard of it. Nature 434: 692-693.
4. Cheng AC, Currie BJ (2005) Melioidosis: Epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-385.
5. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, et al. (2010) Increasing Incidence of Human Melioidosis in Northeast Thailand. American J Trop Med Hyg 82: 1113-1117.
6. Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, Naigowit P, Dance DA, et al. (1993) Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand. J Infect Dis 167: 230-233. (Pubitemid 23002866)
7. Ip M, Osterberg LG, Chau PY, Raffin TA (1995) Pulmonary melioidosis. Chest 108: 1420-1424.
8. Everett ED, Nelson RA (1975) Pulmonary melioidosis. Observations in thirty-nine cases. Am Rev Respir Dis 112: 331-340.
9. Wuthiekanun V, Peacock SJ (2006) Management of melioidosis. Expert Rev Anti Infect Ther 4: 445-455. (Pubitemid 43905466)
10. Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, et al. (2004) Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 48: 1763-1765. (Pubitemid 38544386)
11. Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B (2001) Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am J Trop Med Hyg 64: 24-27. (Pubitemid 32550093)
12. Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, Rajanuwong A, et al. (1999) Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 29: 381-387. (Pubitemid 29380204)
13. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, Dance DA, Smith MD, et al. (1994) Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 19: 846-853. (Pubitemid 24368819)
14. Woods JB (2005) Antimicrobials for Biological Warfare Agents. In: Lindler LE, Lebeda FJ, Korch GW, Editors. Biological Weapons Defense: Infectious Disease and Counterbioterrorism. Humana Press Inc. 285-315.
15. Centers for Disease Control and Prevention (2010) Bioterrorism Agents/Diseases Available: www.bt.cdc.gov/agent/agentlist-category.asp.Accessed 15 January 2013.
16. Centers for Disease Control and Prevention (2012) National Center for Zoonotic, Vector-Borne, and Enteric Diseases Melioidosis Available: www.cdc. gov/nczved/divisions/dfbmd/diseases/melioidosis.Accessed 15 January 2013.
17. Harris P, Engler C, Norton R (2011) Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. Int J Antimicrob Agents 37: 547-549.
18. Mima T, Schweizer HP (2010) The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother 54: 3113-3120.
19. Thamlikitkul V, Trakulsomboon S (2010) In vitro activity of biapenem against Burkholderia pseudomallei. Int J Antimicrob Agents 35: 514.
20. Shih HI, Chuang YC, Cheung BM, Yan JJ, Chang CM, et al. (2009) Sporadic and outbreak cases of melioidosis in southern Taiwan: clinical features and antimicrobial susceptibility. Infection 37: 9-15.
21. Pagès JM, James CE, Winterhalter M (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6: 893-903.
22. Siritapetawee J, Prinz H, Krittanai C, Suginta W (2004) Expression and refolding of Omp38 from Burkholderia pseudomallei and Burkholderia thailandensis, and its function as a diffusion porin. Biochem J 384: 609-617. (Pubitemid 40018975)
23. Siritapetawee J, Prinz H, Samosornsuk W, Ashley RH, Suginta W (2004) Functional reconstitution, gene isolation and topology modelling of porins from Burkholderia pseudomallei and Burkholderia thailandensis. Biochem J 377: 579-587. (Pubitemid 38221830)
24. Suginta W, Mahendran KR, Chumjan W, Hajjar E, Schulte A, et al. (2011) Molecular analysis of antimicrobial agent translocation through the membrane porin BpsOmp38 from an ultraresistant Burkholderia pseudomallei strain. Biochim Biophys Acta 1808: 1552-1559.
25. Prilipov A, Phale PS, Van Gelder P, Rosenbusch JP, Koebnik R (1998) Coupling site-directed mutagenesis with high-level expression: large scale production of mutant porins from E. coli. FEMS Microbiol Lett 163: 65-72. (Pubitemid 28267359)
26. Clinical and Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved stamdard, 7th ed., vol. 26, no. 2. Approved standard M7A7. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Tran QT, Mahendran KR, Hajjar E, Ceccarelli M, Davin-Regli A, et al. (2010) Implication of porins in beta-lactam resistance of Providencia stuartii. J Biol Chem 28: 32273-32281.
28. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, et al. (2006) Effect of 1-(1- naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 57: 339-343. (Pubitemid 43160180)
29. Lugtenberg B, Van Alphen L (1983) Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. Biochim Biophys Acta 737: 51-115. (Pubitemid 13129059)
30. Schulte A, Ruamchan S, Khunkaewla P, Suginta W (2009) The outer membrane protein VhOmp of Vibrio harveyi: pore-forming properties in black lipid membranes. J Membr Biol 230: 101-111.
31. Luckey M, Nikaido H (1980) Diffusion of solutes through channels produced by phage lambda receptor protein of Escherichia coli: inhibition by higher oligosaccharides of maltose series. Biochem Biophys Res Commun 93: 166-171. (Pubitemid 10085592)
32. Yoshimura F, Nikaido H (1985) Diffusion of beta-lactam antibiotics through the porin channels of Escherichia coli K-12. Antimicrob Agents Chemother 27: 84-92. (Pubitemid 15198160)
33. Amsler K, Santoro C, Foleno B, Bush K, Flamm R (2010) Comparison of broth microdilution, agar dilution, and Etest for susceptibility testing of doripenem against gram-negative and gram-positive pathogens. J Clin Microbiol 48: 3353-3357.
34. Luber P, Bartelt E, Genschow E, Wagner J, Hahn H (2003) Comparison of broth microdilution, E Test, and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni and Campylobacter coli. J Clin Microbiol 41: 1062-1068. (Pubitemid 36307107)
35. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52: 1757-1768.
36. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD (2004) Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134-1138. (Pubitemid 40136755)
37. Marley EF, Mohla C, Campos JM (1995) Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 33: 3191-3193.
38. Suginta W, Chumjan W, Mahendran KR, Janning P, Schulte A, et al. (2013) Molecular uptake of chitooligosaccharides through chitoporin from the marine bacterium Vibrio harveyi. PLoS One 8: e55126.
39. Prilipov A, Phale PS, Koebnik R, Widmer C, Rosenbusch JP (1998) Identification and characterization of two quiescent porin genes, nmpC and ompN, in Escherichia coli BE. J Bacteriol 180: 3388-3392. (Pubitemid 28307213)
40. Bajaj H, Tran QT, Mahendran KR, Nasrallah C, Colletier JP, et al. (2012) Antibiotic uptake through membrane channels: role of Providencia stuartii OmpPst1 porin in carbapenem resistance. Biochemistry 51: 10244-10249.
41. Nestorovich EM, Danelon C, Winterhalter M, Bezrukov SM (2002) Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores. Proc Natl Acad Sci U S A 99: 9789-9794. (Pubitemid 34831126)
42. Danelon C, Nestorovich EM, Winterhalter M, Ceccarelli M, Bezrukov SM (2006) Interaction of zwitterionic penicillins with the OmpF channel facilitates their translocation. Biophys J 90: 1617-1627.